Drug Trial Radar · NCT05477524
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,546
Actual
Start
Aug 4, 2022
Primary completion
Jan 7, 2026
Study completion Jan 7, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Valneva Austria GmbH
- First posted
- Jul 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence. Participants will receive a 3-dose primary vaccination series at about 0, 2, and 5 to 9 months and then receive a booster dose about 12 months after end of primary vaccination series. Vaccination of participants will occur at a time of year such that the primary series is completed before the peak Lyme disease season followed by a booster dose just prior to the beginning of the second Lyme disease season. A subset of participants will be followed for a third Lyme disease season. Comparison will be made between the Lyme disease cases of people receiving the study vaccine to those of the people who are not. This will help us determine if the study vaccine is safe and effective. If enrolled, participants will need to visit the research site at least 7 times during the study, and for a subset of participants up to 9 times. There will also be at least 5 telephone contacts. It is expected that each participant will take part in this study for up to about 2 and a half years. The subset of participants followed for a third Lyme disease season will take part in this study for up to about to 3 and a half years.
Conditions
- Lyme Disease
Interventions
VLA15Biological
Shot in the deltoid muscle (preferable in the nondominant arm)
SalineOther
Shot in the deltoid muscle (preferable in the nondominant arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative incidence rate reduction of confirmed Lyme disease cases in the VLA15 group compared to the placebo groupTime frame: Beginning 1 month after receiving the booster dose (28 days after receiving the booster dose through the end of the Lyme disease season following the booster dose (end of October)).
- Percentage of participants reporting local reactionsTime frame: Within 7 days following each study intervention administration
- Percentage of participants reporting systemic eventsTime frame: Within 7 days following each study intervention administration
- Percentage of participants reporting adverse events (AEs)Time frame: Through 1 month following each study intervention administration
- Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)Time frame: Through study completion, up to approximately 42 months.
- Percentage of participants reporting serious adverse events (SAEs)Time frame: Through study completion, up to approximately 42 months.
- Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 2Time frame: At 1 month after completion of the primary series and the booster dose
- Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 3Time frame: At 1 month after completion of the primary series and the booster dose
- Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 2 to Lot 3Time frame: At 1 month after completion of the primary series and the booster dose
- Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6)Time frame: At 1 month after completion of the booster dose
- Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6)Time frame: At 1 month after completion of the booster dose
Locations
129 sites in 7 countries. Site status is shown where the registry gives one.
Care Access - Essex
Essex, Connecticut
Care Access Mobile Site
Ledyard Center, Connecticut
Care Access Mobile Site
New London, Connecticut
Stamford Health Medical Group
Stamford, Connecticut
Stamford Hospital
Stamford, Connecticut
Northern Light Eastern Maine Medical Center
Bangor, Maine
Care Access - Farmington
Farmington, Maine
MaineHealth Pen Bay Hospital
Rockport, Maine
Johns Hopkins
Baltimore, Maryland
Johns Hopkins Hospital
Baltimore, Maryland
Johns Hopkins Rockland Physician Practice and Research Group
Lutherville, Maryland
Sumit Bhutani MD LLC
Westminster, Maryland
Woodholme Gastroenterology Associates
Westminster, Maryland
Pediatric Associates of Fall River
Fall River, Massachusetts
Care Access - Lakeville
Lakeville, Massachusetts
Care Access - Melrose
Melrose, Massachusetts
ActivMed Practices and Research
Methuen, Massachusetts
Care Access - Briarpatch and Mobile Site
Nantucket, Massachusetts
Care Access - Nantucket
Nantucket, Massachusetts
Care Access Mobile Site
Nantucket, Massachusetts
South Shore Medical Center
Norwell, Massachusetts
Care Access Mobile Site
Oak Bluffs, Massachusetts
Care Access - Hingham
Rockland, Massachusetts
Care Access Mobile Site
Sandwich, Massachusetts
Sisu BHR
Springfield, Massachusetts
Care Access Mobile Site
Vineyard Haven, Massachusetts
Care Access - Wareham
Wareham, Massachusetts
South Shore Hospital
Weymouth, Massachusetts
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Clinical Research Institute
Minneapolis, Minnesota
Care Access - Londonderry
Londonderry, New Hampshire
Care Access - North Conway
North Conway, New Hampshire
ActivMed Practices & Research, LLC.
Portsmouth, New Hampshire
Internal Medicine Associates
Bridgeton, New Jersey
Clinilabs
Eatontown, New Jersey
Hunterdon Infectious Disease Specialists
Flemington, New Jersey
Hunterdon Medical Center
Flemington, New Jersey
Care Access - Hoboken
Hoboken, New Jersey
IMA Clinical Research Warren
Warren Township, New Jersey
Velocity Clinical Research, Binghamton
Binghamton, New York
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.